Ngalaba Mba Nile

CT011 bụ ọgwụ GPC3 CAR T-cell nke na-achọ ọgwụgwọ kansa hepatocellular (HCC). CT011 natara ikike IND site na NMPA na 2019 maka ọgwụgwọ nke ndị ọrịa nwere ọrịa kansa siri ike nke GPC3, nke bụ nnwale IND mbụ nke China maka ọgwụgwọ CAR T-cell megide ihe siri ike ...GỤKWUO»

Otu prọfesọ mahadum Russia dị na ngwụcha afọ iri asaa ya na-arịa ọrịa multiple myeloma. Mgbe ọ natara ọtụtụ ọgwụgwọ na ugboro abụọ nke transplant autologous, ọ mụtara maka ọgwụgwọ kachasị mma nke CAR-T na China, yabụ ọ bịara China ịnata mkpụrụ ndụ CAR-T na...GỤKWUO»

Na Julaị 20, China National Medical Products Administration (NMPA) nabatara ojiji ọgwụ ọhụrụ (NDA) nke pCAR-19B nke aka ya mepụtara n'adabereghị onwe ya. Ngwaahịa a bụ ngwaahịa CAR-T mbụ maka leukemia ụmụaka na China, nke a na-eji agwọ ndị ọrịa dị afọ 3-21 ...GỤKWUO»

satricabtagene autoleucel(Satri-cel,CT041) bụ ọgwụ CAR T-cell nke nwere ike ịlụso protein Claudin18.2 ọgụ nke nwere ike ịbụ nke mbụ n'ụwa niile. Satri-cel na-elekwasị anya na etuto siri ike nke Claudin18.2, nke bụ isi ihe na-elekwasị anya na kansa afọ/ọrịa gastroesophageal junction...GỤKWUO»

Na Septemba 6, 2021, JW Therapeutics kwupụtara na National Medical Products Administration (NMPA) nke China akwadola Ngwa Ọgwụ Ọhụrụ (NDA) maka ngwaahịa anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (relma-cel) ...GỤKWUO»

Equecabtagene autoleucel (eque-cel), ọgwụgwọ T-cell nke mkpụrụ ndụ B-cell maturation antigen-targeting chimeric antigen receptor (CAR) sitere na mmadụ, egosila ike maka ọgwụgwọ nke ọrịa myeloma multiple myeloma (R/RMM) nke na-alaghachi azụ ma ọ bụ nke na-adịghị ike. Na June 30, 2023, Ngwaahịa Ahụike Mba China Admi...GỤKWUO»

Na Ọktoba 11, 2024, National Medical Product Administration (NMPA) nke mba China akwadola ngwa Investigational New Drug(IND) maka Inaticabtagene Autoleucel (CNCT19 Injection), ọgwụgwọ sel T-T nke CD19-targeted, iji gwọọ thrombocytopenia Immune ...GỤKWUO»

Na Machị 1, 2024, China National Medical Products Administration (NMPA) kwadoro mwepụta nke ngwaahịa mkpụrụ ndụ CAR-T Zevorcabtagene AutoLeucel (Zevor-cel, CT053) maka ọgwụgwọ nke ndị okenye nwere ọrịa myeloma relapsed ma ọ bụ refractory ndị gara n'ihu mgbe ha mechara ọgwụgwọ opekata mpe ugboro atọ (...GỤKWUO»